Pfizer Stock News

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has a reputation for being the go-to choice for income-focused investors who want both quality and yield.

Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include household names such as Wegovy and Zepbound, two drugs whose sales are rapidly growing.

The past few weeks have been tough for the market. Tariffs are obviously a direct threat to most companies' top and bottom lines, while the broad economic weakness they might cause is nearly impossible to predict.

Just because Wall Street has proved to be a superior wealth creator over the long run doesn't mean stocks are impervious to bouts of volatility. Since President Donald Trump announced his "Liberation Day" tariffs on April 2, we've witnessed some of the wildest swings in the Dow Jones Industrial Average (^DJI -1.73%), S&P 500 (^GSPC -2.24%), and Nasdaq Composite (^IXIC -3.07%) since their respec...

Pfizer has faced headwinds post-COVID, but remains a key player with a robust R&D pipeline and an attractive 7.5%+ dividend yield. The pharmaceutical industry thrives on high R&D investment and patent protections, making Pfizer's development pipeline crucial for long-term growth. Despite recent setbacks, Pfizer's strategic initiatives, including cost-cutting and acquisitions, position it for fu...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. The biopharma has a robust pipeline with potential mega blockbuster cancer drugs and a reduced reliance on Covid-related sales. The company maintains robust cash flows, covering R&D and dividends, and recently sold $6 billion in Haleon shares, boosting liquidity.

On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (PFE 1.51%). Somewhat counterintuitively, this week's rise came after the company announced it was ending the development of a drug in a very hot product category.